// App-Quantinova.ai

5005 : TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.

Researchers

Presenter

  • Joaquin Mateo

Principal Investigators

  • Ursula Brigid McGovern

  • Tony Elliott

  • Robert J Jones

  • Isabel Syndikus

  • Christy Ralph

  • Suneil Jain

  • Mohini Anna Varughese

  • Omi Parikh

  • Simon J. Crabb

  • Susana Miranda

  • George Seed

  • Claudia Bertan

  • Aude Espinasse

  • Peter Chatfield

  • Diletta Bianchini

  • Emma Hall

  • Suzanne Carreira

  • Johann S. De Bono

Medical Centers

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

  • Kings College London, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Clatterbridge Cancer Centre, Merseyside, United Kingdom

  • St. James`s Institute of Oncology and University of Leeds, Leeds, United Kingdom.

  • Queen's University Belfast, Belfast, United Kingdom

  • Royal Preston Hospital, Preston, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Olaparib

  • ribose

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01682772

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved